

2

34 **Abbreviations:**

- 35 PE: preeclampsia
- 36 sPE: Preeclampsia with severe features
- 37 EOPE: early-onset preeclampsia
- 38 LOPE: late-onset preeclampsia
- 39 EHR: electronic health record
- 40 SBP: systolic blood pressure
- 41 DBP: diastolic blood pressure
- 42 RR: respiratory rate
- 43 HELLP: hemolysis, elevated liver enzymes, low platelet count
- 44 AST: aspartate transaminase
- 45 PI: prognosis score
- 46 UM: University of Michigan
- 47 UF: University of Florida
- 48 ICD-10: The International Classification of Diseases, Tenth Revision
- 49 MAP: mean arterial pressure
- 50 UtA-PI: uterine artery pulsatility index
- 51 PLGF: placental growth factor
- 52 ACOG: American College of Obstetricians and Gynecologist
- 53 AUROC: Area Under the Receiver-Operator curve
- 54
- 55
- 56
- 57
-
- 58
- 59

3

60 **Abstract**

61 **Background**

62 Preeclampsia (PE) is one of the leading factors in maternal and perinatal mortality and morbidity

- 63 worldwide with no known cure. Delivery timing is key to balancing maternal and fetal risk in pregnancies
- 64 complicated by PE. Delivery timing of PE patients is traditionally determined by closely monitoring over
- 65 a prolonged time. We developed and externally validated a deep learning models that can predict the time
- 66 to delivery of PE patients, based on electronic health records (EHR) data by the time of the initial
- 67 diagnosis, in the hope of reducing the need for close monitoring.

68 **Method**

69 Using the deep-learning survival model (Cox-nnet), we constructed time-to-delivery prediction models

70 for all PE patients and early-onset preeclampsia (EOPE) patients. The discovery cohort consisted of 1,533

71 PE cases, including 374 EOPE, that were delivered at the University of Michigan Health System (UM)

72 between 2015 and 2021. The validation cohort contained 2,172 PE cases (547 EOPE) from the University

73 of Florida Health System (UF) in the same time period. We built clinically informative baseline models

74 from 45 pre-diagnosis clinical variables that include demographics, medical history, comorbidity, PE

75 severity, and initial diagnosis gestational age features. We also built full models from 60 clinical

76 variables that include additional 15 lab tests and vital signs features around the time of diagnosis.

77

78 **Results**

79 The 7-feature baseline models on all PE patients reached C-indices of 0.74 and 0.73 on UM hold-out

80 testing and UF validation dataset respectively, whereas the 12-feature full model had improved C-indices

81 of 0.79 and 0.74 on the same datasets. For the more urgent EOPE cases, the 6-feature baseline model

82 achieved C-indices of 0.68 and 0.63, and its 13-feature full model counterpart reached C-indices of 0.76

83 and 0.67 in the same datasets.

84

85 **Conclusions**

4

86 We successfully developed and externally validated an accurate deep-learning model for time-to-delivery 87 prediction among PE patients at the time of diagnosis, which helps to prepare clinicians and patients for 88 expected deliveries.

89

90

91 **Introduction**

92 Preeclampsia (PE) is a pregnancy complication affecting 2% to 8% of all pregnancies worldwide and is a 93 leading cause of maternal, fetal, and neonatal mortality and morbidity^{1,2}. PE is defined by new-onset 94 hypertension after 20 weeks of gestation and the presence of proteinuria, and/or other signs of end-organ 95 damage. PE is a diverse syndrome with various subtypes along the spectrum of gestational hypertensive 96 . disorders³. It can be divided into early-onset PE (diagnosed before 34 weeks of pregnancy) or late-onset 97 PE (diagnosed after 34+0 weeks of pregnancy); PE with severe features (sPE) or PE without severe 98 . features^{4,5}. Failure to properly manage PE can lead to a wide variety of severe maternal and neonatal 99 adverse outcomes according to the iHOPE study, while the only known cure for PE is delivery of the 100 placenta^{6–8}. Although earlier delivery can significantly reduce the risk of maternal adverse outcomes, it is 101 associated with increased neonatal unit admission among preterm patients. This, especially in cases of 102 EOPE⁹, creates a dilemma as earlier delivery can potentially prevent severe morbidities including 103 maternal seizure, stroke, organ dysfunction, and intrauterine fetal demise, but may lead to premature birth 104 and subsequent neonatal complications^{10,11}. To balance the risks to both mother and baby, current clinical 105 management of PE includes supportive blood pressure management and prophylaxis for maternal 106 seizures, and a two-dose intramuscular course of betamethasone to augment fetal lung maturation¹². 107

108 Generally, delivery is recommended for PE patients with more than 37+0 weeks of gestation and for 109 severe PE patients with more than $34+0$ weeks of gestation¹². In reality, the delivery timing is a more 110 complex problem, clinicians need to consider both the fetal development, maternal and fetal risk of

5

111 complications, and availability of ICU resources when deciding on delivery timing, particularly among 112 challenging EOPE cases^{12,13}. The decision of delivery is usually made after close monitoring and 113 extensive testing on preeclampsia patients over a prolonged time, which may not be easily accessible and 114 affordable to all patients (particularly those in rural areas or under-developed countries). In addition, 115 current risk assessment tools focus on maternal risk prediction but not the overall delivery urgency 116 considering both moms and fetuses. FullPIERS, miniPIERS and PREP-S are well-established and 117 externally validated models to predict the maternal risk of adverse outcomes among PE patients, in the 118 hope of assisting delivery decisions^{14–19}. These tools are recommended by some, but not all national 119 guidelines^{12,13}. Most of these tools only predict maternal risks, however, clinicians need to consider both 120 maternal and neonatal outcomes when deciding when to deliver. A patient at 34 weeks of gestation would 121 have very different delivery timing compared to a patient at 37 weeks of gestation, even if they have the 122 same risk of adverse outcomes. It is of great importance to directly and precisely predict the time to 123 delivery as early as the first diagnosis of PE, which allows the clinicians to assess the delivery urgency 124 early on and to help them better prioritize resources and treatment, particularly for those doctors 125 practicing in rural or under-developed countries. Additionally, the aforementioned risk predictor models 126 do not assess the risk from baseline features, such as the patient's race, social status, lifestyle, and other 127 comorbidities, which may also have influences on delivery timing.

128

129 Toward this goal, we developed and externally validated the first deep learning model to predict patient 130 delivery time after the initial diagnosis of PE using electronic health records (EHR) data. We utilized the 131 state-of-the-art deep learning-based prognosis prediction model, Cox-nnet (version 2), which we 132 previously developed $20-22$. Cox-nnet methods had previously consistently shown excellent predictive 133 performances under a variety of conditions, including on EHR data²⁰. Our objectives were: (1) to predict 134 the time to delivery at the first diagnosis of PE for all PE patients and an EOPE sub-cohort, by 135 constructing and validating deep-learning models utilizing EHR data; and (2) to assess the quantitative

6

136 contributions of critical EHR features informative of delivery time among PE patients, including those

- 137 EOPE patients.
- 138

139 **Methods**

140 **Data Source**

141 We obtained the discovery cohort of the Precision Health Initiative of Michigan Medicine (UM), the

142 academic healthcare system of the University of Michigan²³. Data usage was approved by the Institutional

143 Review Board (IRB) of the University of Michigan Medical School (HUM#00168171). We obtained the

144 validation cohort from the Integrated Data Repository database at the University of Florida (UF). Data

145 usage was approved by IRB of the University of Florida (#IRB201601899). In both cohorts, we extracted

146 all obstetric records with at least one PE diagnosis between 2015 to 2021 based on ICD-10 diagnosis

147 codes (**Supplementary Table 1**). We excluded patients with the following conditions: Hemolysis,

148 Elevated Liver Enzymes, and Low Platelet (HELLP) syndrome and eclampsia, for which iatrogenic

149 delivery is ubiquitously induced within 48 hours of diagnosis despite fetal condition; chronic

150 hypertension with superimposed PE, whose onset may occur before week 20 and with no clear definitions

151 in the United States²⁴; and postpartum PE, which is only developed after delivery. We also removed

152 patients transferred from other institutions by deleting patients with no visit record within 180 days before

153 the first diagnosis of PE to ensure the accuracy of the initial diagnosis time of PE. The resulting

154 discovery cohort consisted of 1,533 PE cases (including 374 EOPE cases) and the validation cohort

- 155 contained 2,172 PE cases (including 547 EOPE).
- 156

157 **Fully connected Cox-nnet neural network models**

158 We constructed all models using the Cox-nnet v2 algorithm (**Supplementary Figure 1**)²⁰. In this study,

159 we adopted the model to predict the time between PE diagnosis to delivery. To ensure the stability of the

7

160 models, we divided the discovery dataset into a training set (80%) and a hold-out testing set (20%) and 161 applied 5-fold cross-validation on the training set.

162

163 **EHR Feature Engineering**

164 We extracted all available features from UM Precision Health Initiative EMR data. We developed 4

165 models to predict the time to delivery of PE patients: PE baseline, PE full, EOPE baseline and EOPE full

166 models. As suggested by clinicians, the initial baseline models include demographics, medical history,

167 comorbidities, the severity of PE, pregnancy and fetal development characteristics. The full model

168 incorporated all features from the baseline model, with additional lab results and vital signs commonly

169 collected within 5 days before the initial diagnosis of PE (**Supplementary Figure 2A**). EOPE models

170 were built and tested using the same features on patients with PE onset time before 34 weeks of gestation.

171 Features with low powers and high correlation were removed to ensure model accuracy.

172

173 Pregnancy characteristics included parity, number of fetuses, gestational age, PE severity at initial 174 diagnosis, and history of preterm birth, c-section, abruption, etc. Fetal development includes poor fetal 175 growth according to the associated ICD code(O36.59). Other comorbidities were grouped into 29 176 categories using the Elixhauser Comorbidity Index¹. The observational window for lab results and vital 177 signs was 5 days before the day of the initial PE diagnosis. Only the first results of repeated lab tests were 178 used to avoid intervention/treatment effects. Summary statistics of systolic blood pressure (SBP), 179 diastolic blood pressure (DBP), and respiratory rate (RR) measures were included (max, min, mean, 180 standard deviation), as done in previous work². We removed features with high missing proportions (over 181 20%) and sparse features with fewer than 10 non-zero values. Highly correlated variables were identified 182 using the variance inflation factor (VIF) and removed one at a time until all features had a VIF below 3 to 183 avoid multicollinearity. The remaining missing values were imputed using the PMM algorithm from R 184 package "mice". All numerical features were scaled by dividing their root mean square. Numeric features

8

185 with skewness above 3 were log-transformed. As a result, 60 features were kept for initial analysis

186 (**Supplementary Table 2, Supplementary Figure 2B).**

187

188 **Reduced feature representation from the Cox-nnet models**

189 To derive a subset of clinically significant and easily interpretable features, we reduced Cox-nnet features 190 based on both their importance scores and significance levels. To do so, we first selected the top 15 (25% 191 of total features) most important features based on their average permutation importance scores generated 192 by Cox-nnet models. Permutation important scores provide more stable results than other feature 193 selection methods on this dataset, including stepwise selection, lasso regularization, and random forest 194 feature selection²⁵. Then we calculated the log-rank p-value for the 15 features individually and selected 195 the significant ones. We also conducted the ANOVA test on the remaining features to ensure their 196 powers (**Supplementary Table 3**). We rebuilt the clinically informative Cox-nnet models with the 197 reduced set of features, the same way as the models using all initial input features.

198

199 **Model evaluation**

200 We evaluated the cross-validation, hold-out test, and validation results of each model using Harrel's 201 concordance index (C-index). The C-index evaluates the accuracy of predicted events by comparing their 202 relative order to the order of actual events. It is frequently used to assess survival predictions²⁶. The 203 reported C-indices in the training data are the repeated results of the 5-fold cross-validation C-indices on 204 the training sets. To enhance the interpretation of the prognosis prediction, we also stratified patients into 205 high, medium, and low-urgency groups based on the predicted results plotted the Kalper-Meier (KM) 206 curves of time-to-delivery in each group and reported the log-rank p-values. The log-rank test, on the 207 other hand, compares the survival distribution between patient groups, assuming no differences in 208 survival exist^{27(p4)}. Additionally, we used each clinically informative and reduced model result to predict 209 the chances of patients delivering within 2 days, 7 days, and 14 days and obtained the AUROC (area 210 under the receiver operating curve) for each task.

11

265 To enhance the clinical utilities of the Cox-nnet model, we reduced the number of predictive features 266 following the feature reduction procedure in the Method section. This procedure resulted in 7 significant 267 features, which we used to rebuild the "clinically informative Cox-nnet baseline model". It has C-index 268 scores of 0.73, 0.74, and 0.73 on UM cross-validation, hold-out testing, and UF validation dataset 269 respectively (**Figure 2A**). We stratified patients into 3 groups by the quartiles of predicted time-to-270 delivery from the reduced model: high-risk (upper quartile), intermediate-risk (interquartile), and low-risk 271 (lower quartile) groups. The survival curves of the time to delivery interval on these three risk groups 272 display significant differences (log-rank p-value < 0.0001) on both the hold-out testing set (**Figure 2B**) 273 and validation set (**Figure 2E**), confirming the strong discriminatory power of the PI score. To enhance 274 the interpretability of the prognosis modeling, we stratified this model using the threshold of 2/7/14 days 275 and predicted the accuracies of delivery using these classifications. The AUROC scores of these 276 classification tasks are 0.85, 0.88, and 0.89 on the testing set **(Figure 2C)** and 0.67, 0.76, and 0.75 on the 277 validation set **(Figure 2F**), respectively.

278

279 The seven features in the clinically informative baseline model included those that shorten the time to 280 delivery and extend the time to delivery (**Figure 2D; Table 3**). In descending order of importance scores, 281 the features that shorten the time to delivery are gestational age at diagnosis, sPE, uncomplicated 282 pregestational diabetes mellitus, and parity. Conversely, features extending the time to delivery are PE in 283 a prior pregnancy, increasing maternal age, and comorbid valvular disease. To demonstrate the 284 associations of these important features with time to delivery, we dichotomized patient survival in the 285 hold-out testing set by the median value of each feature (**Supplementary Figure 3**). All features, except 286 maternal age, show significant differences (log-rank p-value < 0.05) between the dichotomized survival 287 groups. We further examined the relationship of the top 3 features (gestational age at diagnosis, sPE, and

- 312 groups show more significant distinction in testing (**Figure 3B)** and validation set (**Figure 3E**), than the
- 313 baseline model (**Figure 2B and 2E**). Similarly, we stratified the full model using the threshold of 2/7/14

13

326 score, associated with a longer time to delivery. All dichotomized survival plots using median

327 stratification on each of the 12 important features have log-rank p-values smaller than 0.05, confirming

328 their associations with time to delivery in the discovery set (**Supplementary Figure 5)**. We examined the

329 3 top lab/vital sign features: AST, the standard deviation of DBP, and the standard deviation of RR, on

330 their association with the duration of time between diagnosis and delivery. These values show negative

331 trends with time to delivery, particularly for AST value and the standard deviation of DBP (**Figure 3G-I**).

332 These 3 features are roughly uniformly distributed across delivery gestational ages, except AST which

333 shows slightly higher values in deliveries less than 32 weeks of gestational age (**Supplementary Figure**

334 **6**).

335 Similar to the baseline model earlier using PE patients diagnosed before 37 weeks of gestation, we again 336 alternatively built another full model with the same patients before 37 weeks of gestation. We observed 337 very similar results as the full model using all PE patients, in terms of C-index, the selected top features 338 and their feature scores (**Supplementary Figure 4 E-H**).

14

340 **Time to delivery prediction of EOPE patients**

341 Accurate prediction of EOPE patients' time to delivery is crucial, given that delivery of a premature infant 342 has more significant neonatal consequences. Using similar modeling techniques, we trained two additional 343 EOPE-specific Cox-nnet v2 models (baseline vs. full model), using the same features described earlier 344 (**Supplementary Table 2**), on a subset of 374 EOPE patients from the UM discovery cohort. 345 The C-indices for the clinically informative EOPE baseline model are 0.67, 0.68, and 0.63 on the UM 346 cross-validation, hold-out testing, and UF validation sets, respectively (**Figure 4A**). Such significantly 347 lower C-indices for EOPE compared to PE are expected, as EOPE cases are usually difficult to predict 348 prognosis. Still, the time-to-delivery prediction for EOPE is on par or better than the prediction of PE diagnosis using the same set of EHR data³³, demonstrating its potential clinical utility. The KM curves of 350 different predicted survival groups have significant distinctions in both the testing and validation datasets 351 (**Figure 4B** and **4E).** This baseline model consists of the six most important features: gestational age at 352 diagnosis, sPE, PE in a past pregnancy, parity, pulmonary circulatory disorders, and coagulopathies 353 (**Figure 4D; Table 3**). All survival plots, dichotomized using the median stratification on each of the 6 354 features, have log-rank p-values smaller than 0.05 in the discovery dataset (**Supplementary Figure 7)**. 355 Additionally, the AUROCs of binarized classification on delivery in the next 2/7/14 days range from 356 0.64-0.82 on the testing set (**Figure 4C**) and 0.52-0.68 on the validation set **(Figure 4F).** 357

358 The clinically informative EOPE full model reached much higher accuracy compared to the EOPE 359 baseline model, with median C-indices of 0.74, 0.76, and 0.67 on the cross-validation, testing, and 360 validation sets (**Figure 4G**). The large increases in C-indices are the results of including additional lab 361 tests and blood pressure measurements right around the time of diagnosis of EOPE, confirming their 362 significant clinical values. The 3 risk-stratified groups within the EOPE patient's cohort also showed 363 significant (log-rank p-value<0.001) differences in the hold-out testing set and validation set (**Figure 4H,** 364 **4K).** The AUROCs of chance of delivery in the next 2/7/14 days are significantly improved, ranging

15

374 We created dichotomized survival curves based on creatinine value and platelet count, two new features 375 relative to the EOPE baseline model. Both show strong distinctions between the risk groups (**Figure 4I,** 376 **4L**), similar to all other selected features (**Supplementary Figure 7- 8**). These two features also revealed 377 systematic trends in associations with the gestational age at delivery and time from diagnosis to delivery**.** 378 Patients with high creatinine levels were more likely to be delivered within 3 days or less of diagnosis and 379 more likely to deliver preterm (**Figure 4M-4O**). Lower platelet counts were also associated with shorter 380 time to delivery (**Figure 4Q**), even though the platelet levels were not strongly associated with gestational 381 age at delivery among all EOPE patients (**Figure 4R**).

382

383 **PE time to deliver predictor graphic user interface (GUI)**

384 To disseminate our model publicly, we packaged the pre-trained clinically informative models above into 385 an interactive, user-friendly web application using R shiny²³. We named this app "PE time to delivery" 386 predictor". The app contains two main panels: the single-patient prediction panel and the group prediction 387 panel (**Supplementary Figure 9**). The single-patient prediction panel calculates the prognosis index (PI) 388 of a single patient if provided the required clinical variables. The PI score describes the patient's risk of 389 delivery at the time of the diagnosis of PE, relative to the population. The panel also provides the 390 percentile of the PI score among the training data and displays the results in a histogram figure and a

16

- 397 predict time-to-delivery at the initial diagnosis of PE directly. We calculated the maternal risk of adverse
- 398 outcomes using the fullPIERS formula on the UM EHR data. We then used this risk score to estimate the
- 399 time-to-delivery and compared its performance with our proposed model (see **Methods**). The cross-
- 400 validation C-index of fullPIERS is 0.50±0.005 on all PE patients and 0.60±0.01 on the EOPE subset

401 (**Supplementary Figure 10A**), much worse than those from our models. So are the survival curves

402 grouped by predicted risk (**Supplementary Figure 10B-C**). Thus the time-to-delivery models are not

403 only different but also irreplaceable by the maternal risk prediction models.

- 404
- 405

406 **Discussion**

407 PE is a highly heterogenous pregnancy syndrome currently without cure except for delivering the baby 408 . and placenta^{3,34}. Here we report a new type of survival model to precisely predict the time to delivery as 409 early as the initial diagnosis of PE, subsequent to our recent success in predicting the onset of PE using 410 the same set of EHR data³³. It helps to save the effort of close monitoring and extensive testing which is 411 conventionally done in resource-rich settings. The simple yet precise models can also be utilized in 412 healthcare systems in resource-limited countries and regions. With such information, clinicians may 413 allocate limited resources in busy antepartum and neonatal ICU beds, or make decisions about the 414 urgency to transfer a patient to a higher level of care in the lack of sufficient resources. As many pregnant 415 women are willing to accept personal risks to improve perceived fetal outcomes, a more concrete model

17

435 There are several noticeable strengths of this study. The models show consistently high performance in 436 survival prediction and classification tasks, better than previous time-to-delivery prediction models using 437 clinical data or biomarkers^{37–39}. Unlike the majority of previous studies that are not validated with 438 external data^{35,40,41}, our models are validated with an external and independent EHR dataset from UF 439 Health System, despite the noticeable differences between the populations in the two cohorts (**Table 1, 2**). 440 These models also address clinical interpretability by providing importance scores with directionality for

18

19

490 Codes used for analysis are available at https://github.com/lanagarmire/PE_delivery

20

491

492 **Declaration of Interest**

- 493 The authors declare no conflict of interest.
- 494
- 495 **Funding**
- 496 LXG was supported by grants R01 LM012373 and LM012907 awarded by NLM, R01 HD084633
- 497 awarded by NICHD. DJL was supported by the National Institute of Diabetes and Digestive and Kidney
- 498 Diseases (K01DK115632) and the University of Florida Clinical and Translational Science Institute
- 499 (UL1TR001427). XY is supported by NIH/NIGMS Grant T32GM141746. AM is supported by the
- 500 National Center for Advancing Translational Science (5TL1TR001428).
- 501

502 **Author's Contribution**

503 LG conceived this project and supervised the study, after discussing it with ESL. XY conducted data

504 analysis, implemented the Shiny app, and wrote the manuscript. HKB, ADM, KX, and DJL collaborated

505 on validation using the UF cohort. ESL and ADM provided clinical assessments and assistance. DG

506 assisted with Shiny app editing and troubleshooting. All authors have read, revised, and approved the

507 manuscript.

508

509 **Reference**

- 510 1. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia—Pathophysiology and Clinical 511 Presentations. *Journal of the American College of Cardiology*. 2020;76(14):1690-1702. 512 doi:10.1016/j.jacc.2020.08.014
- 513 2. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for 514 Preeclampsia: US Preventive Services Task Force Recommendation Statement. *JAMA*. 515 2017;317(16):1661. doi:10.1001/jama.2017.3439
- 516 3. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, for the Global Pregnancy 517 Collaboration. Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness.
- 518 *Hypertension*. 2021;77(5):1430-1441. doi:10.1161/HYPERTENSIONAHA.120.14781

- 519 4. Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. *American* 520 *Journal of Obstetrics and Gynecology*. 2011;205(3):191-198. doi:10.1016/j.ajog.2011.07.017
- 521 5. von Dadelszen P, Magee LA, Roberts JM. Subclassification of Preeclampsia. *Hypertension in* 522 *Pregnancy*. 2003;22(2):143-148. doi:10.1081/PRG-120021060
- 523 6. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics
- 524 and therapies. *Nat Rev Nephrol*. 2019;15(5):275-289. doi:10.1038/s41581-019-0119-6
525 7. Amaral LM, Wallace K, Owens M, LaMarca B. Pathophysiology and Current Clinical 525 7. Amaral LM, Wallace K, Owens M, LaMarca B. Pathophysiology and Current Clinical Management
526 of Preeclampsia. *Curr Hypertens Rep.* 2017:19(8):61. doi:10.1007/s11906-017-0757-7
- 526 of Preeclampsia. *Curr Hypertens Rep*. 2017;19(8):61. doi:10.1007/s11906-017-0757-7 527 8. Duffy J, Cairns A, Richards Doran D, et al. A core outcome set for pre Declampsia research: an international consensus development study. $BJOG$. 2020;127(12):1516-1526. doi:10.1111/1471-528 international consensus development study. *BJOG*. 2020;127(12):1516-1526. doi:10.1111/1471- 529 0528.16319
- 530 9. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-531 versus late-onset disease. *American Journal of Obstetrics and Gynecology*. 2013;209(6):544.e1- 532 544.e12. doi:10.1016/j.ajog.2013.08.019
533 10. Manuck TA, Rice MM, Bailit JL, et al. P
- 533 10. Manuck TA, Rice MM, Bailit JL, et al. Preterm neonatal morbidity and mortality by gestational age: 534 a contemporary cohort. *American Journal of Obstetrics and Gynecology*. 2016;215(1):103.e1- 535 103.e14. doi:10.1016/j.ajog.2016.01.004
- 536 11. Hollegaard B, Lykke JA, Boomsma JJ. Time from pre-eclampsia diagnosis to delivery affects future 537 health prospects of children. *Evolution, Medicine, and Public Health*. 2017;2017(1):53-66. 538 doi:10.1093/emph/eox004
539 12. Gestational Hypertension a
- 539 12. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstetrics &* 540 *Gynecology*. 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891
- 541 13. Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during
542 regnancy: summary of NICE guidance. *BMJ*. 2010;341(aug25 3):c2207-c2207. 542 pregnancy: summary of NICE guidance. *BMJ*. 2010;341(aug25 3):c2207-c2207. 543 doi:10.1136/bmj.c2207
- 544 14. Von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: 545 development and validation of the fullPIERS model. *The Lancet*. 2011;377(9761):219-227. 546 doi:10.1016/S0140-6736(10)61351-7
- 547 15. Ukah UV, Payne B, Hutcheon JA, et al. Assessment of the fullPIERS Risk Prediction Model in
548 Women With Early-Onset Preeclampsia. *Hypertension*. 2018;71(4):659-665. 548 Women With Early-Onset Preeclampsia. *Hypertension*. 2018;71(4):659-665. 549 doi:10.1161/HYPERTENSIONAHA.117.10318
- 550 16. Ukah UV, Payne B, Karjalainen H, et al. Temporal and external validation of the fullPIERS model 551 for the prediction of adverse maternal outcomes in women with pre-eclampsia. *Pregnancy* 552 *Hypertension*. 2019;15:42-50. doi:10.1016/j.preghy.2018.01.004
- 553 17. Payne BA, Hutcheon JA, Ansermino JM, et al. A Risk Prediction Model for the Assessment and 554 Triage of Women with Hypertensive Disorders of Pregnancy in Low-Resourced Settings: The
555 miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Multi-country Prospective Cohort Stu 555 miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Multi-country Prospective Cohort Study.
556 Lawn JE. ed. *PLoS Med.* 2014:11(1):e1001589. doi:10.1371/journal.pmed.1001589
- 556 Lawn JE, ed. *PLoS Med*. 2014;11(1):e1001589. doi:10.1371/journal.pmed.1001589 18. for the PREP Collaborative Network, Thangaratinam S, Allotey J, et al. Prediction of complications 558 in early-onset pre-eclampsia (PREP): development and external multinational validation of 559 prognostic models. *BMC Med*. 2017;15(1):68. doi:10.1186/s12916-017-0827-3
- 560 19. Schmidt LJ, Rieger O, Neznansky M, et al. A machine-learning-based algorithm improves prediction 561 of preeclampsia-associated adverse outcomes. *Am J Obstet Gynecol*. 2022;227(1):77.e1-77.e30. 562 doi:10.1016/j.ajog.2022.01.026
- 563 20. Wang D, Jing Z, He K, Garmire LX. Cox-nnet v2.0: improved neural-network-based survival 564 prediction extended to large-scale EMR data. Schwartz R, ed. *Bioinformatics*. 2021;37(17):2772- 565 2774. doi:10.1093/bioinformatics/btab046
- 566 21. Ching T, Zhu X, Garmire LX. Cox-nnet: An artificial neural network method for prognosis prediction 567 of high-throughput omics data. Markowetz F, ed. *PLoS Comput Biol*. 2018;14(4):e1006076. 568 doi:10.1371/journal.pcbi.1006076
- 569 22. Zhan Z, Jing Z, He B, et al. Two-stage Cox-nnet: biologically interpretable neural-network model for

- 570 prognosis prediction and its application in liver cancer survival using histopathology and
571 transcriptomic data. *NAR Genomics and Bioinformatics*. 2021;3(1):lqab015.
	- 571 transcriptomic data. *NAR Genomics and Bioinformatics*. 2021;3(1):lqab015.
- 572 doi:10.1093/nargab/lqab015
573 23. Zawistowski M, Fritsche LG
- 573 23. Zawistowski M, Fritsche LG, Pandit A, et al. The Michigan Genomics Initiative: A biobank linking 574 genotypes and electronic clinical records in Michigan Medicine patients. *Cell Genomics*.
- 575 2023;3(2):100257. doi:10.1016/j.xgen.2023.100257
576 24. ACOG Practice Bulletin No. 203: Chronic Hyperten 576 24. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. *Obstetrics & Gynecology*. 577 2019;133(1):e26-e50. doi:10.1097/AOG.00000000000003020
578 25. Altmann A, Tolosi L, Sander O, Lengauer T. Permutation imp
- 578 25. Altmann A, Toloşi L, Sander O, Lengauer T. Permutation importance: a corrected feature importance
579 measure. *Bioinformatics*. 2010;26(10):1340-1347. doi:10.1093/bioinformatics/btq134 579 measure. *Bioinformatics*. 2010;26(10):1340-1347. doi:10.1093/bioinformatics/btq134
580 26. Harrell FE. Evaluating the Yield of Medical Tests. *JAMA*. 1982;247(18):2543.
- 580 26. Harrell FE. Evaluating the Yield of Medical Tests. *JAMA*. 1982;247(18):2543. 581 doi:10.1001/jama.1982.03320430047030
- 582 27. Peto R, Peto J. Asymptotically Efficient Rank Invariant Test Procedures. *Journal of the Royal* 583 *Statistical Society Series A (General)*. 1972;135(2):185. doi:10.2307/2344317
- 584 28. Winston Chang, Joe Cheng, JJ Allaire, Yihui Xie, Jonathan McPherson. shiny: Web Application
585 Framework for R. Published online 2020. https://CRAN.R-project.org/package=shiny 585 Framework for R. Published online 2020. https://CRAN.R-project.org/package=shiny
- 586 29. R Core Team. R: A language and environment for statistical computing. Published online 2021. 587 https://www.R-project.org/
588 30. Rossum G van. Drake FL. 7
- 588 30. Rossum G van, Drake FL. The Python language reference. Published online 2010.
- 589 31. Wickham H, François R, Lionel Henry, Kirill Müller. dplyr: A Grammar of Data Manipulation.
590 Published online 2020. https://CRAN.R-project.org/package=dplyr 590 Published online 2020. https://CRAN.R-project.org/package=dplyr
591 32. Buuren S van. Groothuis-Oudshoorn K. mice F.: Multivariate Imput
- 591 32. Buuren S van, Groothuis-Oudshoorn K. **mice**□: Multivariate Imputation by Chained Equations in *R*.
592 *J Stat Soft.* 2011:45(3). doi:10.18637/iss.v045.i03 592 *J Stat Soft*. 2011;45(3). doi:10.18637/jss.v045.i03
- 593 33. Ballard HK, Yang X, Mahadevan A, Lemas DJ, Garmire LX. Building and validating 5-feature
594 models to predict preeclampsia onset time from electronic health record data. Published online N models to predict preeclampsia onset time from electronic health record data. Published online March 595 24, 2023. doi:10.1101/2023.03.23.23287655
596 34. Benny PA, Alakwaa FM, Schlueter RJ, Lassi
- 596 34. Benny PA, Alakwaa FM, Schlueter RJ, Lassiter CB, Garmire LX. A review of omics approaches to
597 study preeclampsia. *Placenta*. 2020:92:17-27. doi:10.1016/i.placenta.2020.01.008 597 study preeclampsia. *Placenta*. 2020;92:17-27. doi:10.1016/j.placenta.2020.01.008
- 598 35. Li S, Wang Z, Vieira LA, et al. Improving preeclampsia risk prediction by modeling pregnancy
599 trajectories from routinely collected electronic medical record data. *npj Digit Med*. 2022;5(1):68 599 trajectories from routinely collected electronic medical record data. *npj Digit Med*. 2022;5(1):68. 600 doi:10.1038/s41746-022-00612-x
- 601 36. Jhee JH, Lee S, Park Y, et al. Prediction model development of late-onset preeclampsia using 602 machine learning-based methods. Spradley FT, ed. *PLoS ONE*. 2019;14(8):e0221202. 603 doi:10.1371/journal.pone.0221202
- 604 37. Duhig KE, Seed PT, Placzek A, et al. Prognostic indicators of severe disease in late preterm pre-605 eclampsia to guide decision making on timing of delivery: The PEACOCK study. *Pregnancy* 606 *Hypertension*. 2021;24:90-95. doi:10.1016/j.preghy.2021.02.012
- 607 38. Reeder HT, Haneuse S, Modest AM, Hacker MR, Sudhof LS, Papatheodorou SI. A novel approach to joint prediction of preeclampsia and delivery timing using semicompeting risks. American Journal of 608 joint prediction of preeclampsia and delivery timing using semicompeting risks. *American Journal of* 609 *Obstetrics and Gynecology*. Published online August 2022:S0002937822006883. 610 doi:10.1016/j.ajog.2022.08.045
- 611 39. Lim S, Li W, Kemper J, Nguyen A, Mol BW, Reddy M. Biomarkers and the Prediction of Adverse 612 Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. *Obstetrics & Gynecology*. 613 2021;137(1):72-81. doi:10.1097/AOG.00000000000004149
614 40. Binder J, Palmrich P, Pateisky P, et al. The Prognostic Valu
- 614 40. Binder J, Palmrich P, Pateisky P, et al. The Prognostic Value of Angiogenic Markers in Twin 615 Pregnancies to Predict Delivery Due to Maternal Complications of Preeclampsia. *Hypertension*. 616 2020;76(1):176-183. doi:10.1161/HYPERTENSIONAHA.120.14957
- 617 41. Wright D, Wright A, Nicolaides KH. The competing risk approach for prediction of preeclampsia. 618 *American Journal of Obstetrics and Gynecology*. 2020;223(1):12-23.e7.
- 619 doi:10.1016/j.ajog.2019.11.1247

23

American Indian or Alaska Native 0.00 0.00 Asian 0.07 0.02 Caucasian 0.75 0.49

Unknown or Other 0.00 0.12

Hispanic 0.06 0.11 Non-Hispanic 0.94 0.87 Unknown 0.00 0.01

Current Smoker 0.06 0.13 Former Smoker 0.24 NA Never Smoker 0.70 0.87

Yes 0.10 0.17 No 0.90 0.83

Yes 0.11 0.12 No 0.89 0.88

Yes 0.47 0.35 No 0.53 0.65

0.00 0.00

Native Hawaiian and Other Pacific

Islander

Ethnicity, N (%)

Smoking Status, N (%)

History of PE, N (%)

sPE, N (%)

Illegal Drug Use Status, N(%)

- 630
- 631
- 632
-
- 633
- 634
- 635
- 636
- 637
- 638
- 639
-

640
641 641 **Table 2: Basic Characteristics of EOPE patients in this study**

642

643

644

645

646

25

658

659

661

Table 3: Features and their permutation importance score in each reduced model

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.03.22273366;](https://doi.org/10.1101/2022.04.03.22273366) this version posted August 9, 2024. The copyright holder for this preprint

27

711 is associated with a shorter time to delivery and a negative sign means an extension of time to delivery.
712 G-I: The distribution of aspartate aminotransferase (AST) values, the standard deviation of diastolic blo

- 712 G-I: The distribution of aspartate aminotransferase (AST) values, the standard deviation of diastolic blood
- 713 pressure (DBP) and the standard deviation of respiratory rate (RR), in association with time (days) to delivery. delivery.
- 715

716 **Figure 4: Results, interpretation and evaluation of baseline and full models on the EOPE patient**

717 **subset.** A: The bar plots of C-indices from the original Cox-nnet EOPE baseline model (red) and feature-
718 reduced clinically informative model (green) on the cross-validation and testing set and validation set. B-718 reduced clinically informative model (green) on the cross-validation and testing set and validation set. B-
719 C: The survival curves of high-risk (top 25%), intermediate-risk (middle 50%) and low-risk groups 719 C: The survival curves of high-risk (top 25%), intermediate-risk (middle 50%) and low-risk groups 720 (bottom 25%), categorized by predicted PI from the reduced EOPE baseline model in A. B, E: hold-out testing data, E: validation data. C, F: ROC curves of prediction delivery time within 2 days, 7 days and 1 721 testing data, E: validation data. C, F: ROC curves of prediction delivery time within 2 days, 7 days and 14 722 days using results from reduced EOPE baseline model (A) on C: hold-out testing data and F: validation 723 data. D: The ln-transformed permutation importance score of features in the EOPE full model. G: The bar
724 plots of C-indices from the original Cox-nnet EOPE full model (red) and its feature-reduced clinically 724 plots of C-indices from the original Cox-nnet EOPE full model (red) and its feature-reduced clinically
725 informative model (green) on the cross-validation and testing set and validation set. H, K: The survival 725 informative model (green) on the cross-validation and testing set and validation set. H, K: The survival 726 curves of high-risk (top 25%), intermediate-risk (middle 50%) and low-risk groups (bottom 25%), categorized by predicted PI from the reduced full model in E. H: hold-out testing data, K: validation categorized by predicted PI from the reduced full model in E. H: hold-out testing data, K: validation data. 728 I, L: ROC curves of prediction delivery time within 2 days, 7 days and 14 days using results from reduced EOPE full model (G) on I: hold-out testing data and L: validation data. J: The ln-transformed permutation EOPE full model (G) on I: hold-out testing data and L: validation data. J: The ln-transformed permutation 730 importance scores of features in the EOPE full model. M-O: Analysis of creatinine values among the 731 EOPE patients in the discovery cohort. M: The dichotomized survival curves by the median value of 731 EOPE patients in the discovery cohort. M: The dichotomized survival curves by the median value of creatinine. N, O: Distributions of creatinine values by delivery gestational week (N) and time to deli-732 creatinine. N, O: Distributions of creatinine values by delivery gestational week (N) and time to delivery 733 (O). P-R: Analysis of platelet counts among the EOPE patients in the discovery cohort. P: The dichotomized survival curves by the median value of platelet counts. Q-R: Distributions of creat 734 dichotomized survival curves by the median value of platelet counts. Q-R: Distributions of creatinine 735 values by delivery gestational week (Q) and time to delivery (R).

736 737

738 **Figure 5: Comparison of important features among the four feature-reduced clinically informative**

739 **models** A: The bubble plot of important features from PE baseline, EOPE baseline, PE full, and EOPE full models using reduced top important features. The size of the bubbles represents the permutation

740 full models using reduced top important features. The size of the bubbles represents the permutation
741 importance score of each feature. Color represents the sign of features in the time to delivery prediction

importance score of each feature. Color represents the sign of features in the time to delivery prediction: a

742 positive sign indicates that a higher value in the feature is associated with a shorter time to delivery and a

743 negative sign means an extension of time to delivery. B: Venn diagram of the important features from the

- four models shown in A.
- 745

Time to Delivery(Day)

Time to Delivery(Day)

A

Time to Delivery(Day)

 ϵ

 $0.5 - 1$ $\frac{1}{2}$ $\overline{\mathbf{3}}$ $\overline{6}$ $\ddot{}$ -7 $\frac{1}{8}$ $\overline{9}$

 $\frac{1}{4}$

Time to Delivery(Day)

100

200